TSRI announces five-year agreement with Janssen to research on influenza virus

Published on May 7, 2013 at 8:52 AM · No Comments

The Scripps Research Institute (TSRI) today announced a five-year agreement with Janssen Pharmaceuticals, Inc. (Janssen) to collaborate on focused research projects in the infectious disease area, with the initial project targeting the influenza virus. Under the agreement Janssen will receive certain license rights to the results of the research. Janssen Pharmaceuticals will collaborate in the research on influenza through its Crucell Vaccine Institute.  

"We're delighted to partner with Janssen in this work that could have a significant impact on human health," said Michael A. Marletta , president and CEO of TSRI. "The new agreement leverages the institute's significant strengths in structural biology to move forward new therapies and vaccines."

Scott Forrest , TSRI's vice president for business development, added, "This deal is the latest example of our corporate partnership strategy, in which we seek focused collaborations to match companies' specific areas of interest with areas of expertise among multiple TSRI labs."

The new agreement builds on research on the influenza virus conducted jointly by TSRI and Janssen's Crucell Vaccine Institute. Previous collaborations have resulted in several high-impact publications, most recently in August 2012 in the journal Science.

Read in | English | Deutsch | Português | 한국어 | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post